Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Scancell Holdings Plc (SCLP.LN)

Scancell Holdings Plc (SCLP.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Scancell Holdings Plc Sanders Road Unit 202, Bellhouse Building Oxford OX4 4GD GBR

https://www.scancell.co.uk P: 186-558-2066

Description:

Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Key Statistics

Overview:

Market Capitalization, $K 85,002
Shares Outstanding, K 928,980
Annual Sales, $ 5,271 K
Annual Net Income, $ -11,936 K
% of Insider Shareholders 14.70%
% of Institutional Shareholders 0.88%

Growth:

1-Year Return -42.36%
3-Year Return -56.94%
5-Year Return 105.62%

Per-Share Information:

Latest Earnings Date N/A
Earnings Per Share ttm -0.01
Dividend Payout Ratio 0.00%
Most Recent Split 10-1 on 07/26/11

SCLP.LN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % -269.84%
Return-on-Assets % -31.41%
Profit Margin % -226.45%
Debt/Equity N/A
Price/Sales N/A
Price/Book N/A
Book Value/Share -0.01
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar